Test Price
2,800 AED✅ Home Collection Available
ZSWIM6 Gene Acromelic Frontonasal Dysostosis Genetic Test in Dubai | 2,800 AED | DHA Licensed Lab
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Physician.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test screens the ZSWIM6 gene for pathogenic variants responsible for acromelic frontonasal dysostosis (AFND), a rare dysmorphology syndrome characterized by craniofacial and limb anomalies, using high‑throughput Next Generation Sequencing (NGS).
| Feature | Our Test (NGS) | Alternative (Sanger Sequencing) |
|---|---|---|
| Detection Scope | Full gene coverage - all exons, splice sites, and regulatory regions | Limited to pre‑selected exons; may miss deep intronic or regulatory variants |
| Sensitivity | >99.9% analytical sensitivity for single nucleotide variants and small indels | ~98% for targeted regions; lower for uncommon mutations |
| Turnaround Time | 3-4 weeks with integrated bioinformatics pipeline | 4-6 weeks; often requires sequential testing |
| Compliance | Full compliance with UAE Federal Decree-Law No. 45 of 2021 (PDPL), Federal Law No. 2 of 2019, and Federal Decree-Law No. 4 of 2016. DHA licensed. | Compliance varies; may not meet UAE genetic testing regulations. |
Physician Insight & Safety Protocols
Note from Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403): "I understand the anxiety that accompanies concerns about a child's development. This test provides a definitive molecular diagnosis for acromelic frontonasal dysostosis, guiding clinical management and family planning. However, results must always be interpreted in the context of a comprehensive clinical evaluation and genetic counselling."
Advisory & Safety Notices
⚠ Important Medication Warning
Do not discontinue or modify any prescribed medication without consulting your doctor. This genetic test does not replace ongoing clinical treatment or routine medical care.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Severe coagulopathy precluding safe blood draw; neonates less than 48 hours old for FTA card collection; inability of guardian to provide informed consent (strict adherence to Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Emergency Red Flags – seek immediate medical attention if experiencing: Sudden severe craniofacial pain, rapid neurological deterioration, respiratory distress, signs of increased intracranial pressure (persistent vomiting, lethargy, bulging fontanelle in infants). These symptoms are unrelated to the test procedure but require urgent care.
Patient FAQ & Clinical Guidance
1. What is the purpose of the ZSWIM6 gene test?
This NGS test identifies pathogenic ZSWIM6 mutations causing acromelic frontonasal dysostosis for accurate molecular diagnosis. It enables clinicians to confirm the condition, differentiate it from other craniofacial syndromes, and develop a personalized multispecialty management plan including paediatric surgery, endocrinology, and developmental follow-up.
2. How is the test performed and what sample is required?
A blood, DNA, or FTA card drop sample is collected by our VIP Mobile Phlebotomy team. A small volume of whole blood, previously extracted DNA, or a single drop of blood dried on an FTA card is obtained through a painless procedure by a certified phlebotomist at your home (8 AM - 11 PM). The sample is transported in temperature-controlled containers to our ISO-accredited laboratory.
3. Is genetic counselling required before the test?
A pre-test genetic counselling session is required to review family history and explain potential outcomes. Our board-certified genetic counsellors will draw a detailed pedigree chart, discuss the inheritance pattern (autosomal dominant), and outline the possible results (positive, negative, or variant of uncertain significance). This session is mandatory under UAE Federal Decree-Law No. 4 of 2016 on Medical Liability and ensures informed consent.
UAE Regulatory & Data Privacy Adherence
This service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DHA Facility License Number: 1143. Physical Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE.
ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | ZSWIM6 Gene Acromelic Frontonasal Dysostosis Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 weeks |
| Sample Type / Matrix | Peripheral whole blood, extracted DNA, or dried blood spot (FTA card) |
| Methodology Used | Next Generation Sequencing (NGS) with targeted gene panel |
| ICD-10-CM Code | Q87.0 |
| LOINC Code | 81397-3 |
| DHA Facility License & Laboratory Address | DHA License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians